4.1 What modern treatment actually does

External insulin transformed T1D from a rapidly fatal disease into a manageable chronic condition. Rapid-acting and long-acting insulin analogues, continuous glucose monitors (CGMs), pumps, and automated insulin-delivery algorithms can substantially improve glycemic control.

A CGM measures glucose in fluid between cells rather than directly in blood. It reports a new estimate every few minutes and shows a trend arrow. A pump can deliver small background doses and larger meal doses. An automated system increases or decreases delivery based on recent sensor data and a mathematical model.

These systems apply physiologic principles through sensors, pharmacology, and control algorithms.

4.2 The three delays

Even the best system must work around three unavoidable delays:

Schematic

Physiologic regulation and exogenous insulin delivery

  1. 1

    Meal or exercise changes demand

  2. 2

    CGM detects the change after a lag

  3. 3

    Person or algorithm chooses a dose

  4. 4

    Insulin absorbs from under the skin

  5. 5

    Effect continues even if demand changes again

External insulin works, but it arrives by a slower route and cannot be recalled.
  1. Measurement delay: interstitial glucose follows blood glucose with some lag, especially during rapid change.
  2. Decision delay: a person or algorithm must interpret the signal and choose an action.
  3. Drug-action delay: insulin placed under the skin must absorb into circulation and act on tissues.

Meanwhile, the future keeps changing. A meal may digest faster or slower than expected. Exercise can increase insulin sensitivity during activity and for hours afterward. Stress hormones or illness can raise glucose. The system predicts from incomplete information.

4.3 Why dosing is a moving calculation

For a meal, a person may estimate carbohydrate, consider current glucose and trend, subtract insulin already active in the body, and adjust for exercise, illness, time of day, and experience. The same nominal meal can require different insulin on different days.

Once injected insulin is absorbed, it cannot be recalled. If the meal is delayed, vomiting occurs, or unexpected exercise begins, the dose may now be too strong. Carbohydrate can rescue the low, but this is a correction to a correction.

Concept questionWhy can an automated pump reduce insulin delivery but still fail to prevent every low?

Explanation

Insulin delivered earlier may still be active. Stopping the pump prevents additional insulin, but it cannot remove molecules already absorbed into blood and tissues.

4.4 What a small amount of biological function can add

A graft does not need to replace every unit of insulin to help. Even modest endogenous secretion can rise and fall with glucose, providing a responsive buffer. That may reduce variability and protect against severe hypoglycemia before full insulin independence is achieved.

This creates an endpoint ladder:

Increasing levels of biological and clinical benefit

  1. 1

    The implanted cells survive.

  2. 2

    C-peptide becomes detectable.

  3. 3

    C-peptide rises appropriately after a meal.

  4. 4

    Glucose variability and severe hypoglycemia improve.

  5. 5

    External insulin needs fall substantially.

  6. 6

    Insulin independence is sustained.

  7. 7

    The benefit persists for years without chronic systemic immunosuppression.

Each step matters, but a lower step does not prove the higher ones.

4.5 Why early trials enroll people at highest risk

Cell replacement can involve a procedure, lifelong monitoring, and immunosuppressive drugs. Those drugs can increase infection risk, injure kidneys, and create other serious complications. The benefit must justify the burden.

Early studies therefore often enroll adults with impaired awareness of hypoglycemia and recurrent severe episodes despite intensive care. Restoring biological sensing may offer them a major benefit. A person doing well with an automated system faces a different risk–benefit calculation.

A

Functional cure

Meaningful endogenous control, often including insulin independence, while another major treatment such as immunosuppression may remain.

B

Durable, scalable cure

Long-lived control without chronic systemic immunosuppression, with acceptable lifetime safety and a manufacturable supply.

Review questions

Review the chapter concepts.

  1. What information does a CGM measure, and why can it lag?
  2. Describe the three delays in external insulin therapy.
  3. Why can stopping a pump fail to remove hypoglycemia risk immediately?
  4. How can a partially functioning graft help without producing insulin independence?
  5. Why are the first cell-therapy populations selected for severe clinical need?

Use these questions to identify concepts that require additional review.